| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725409 | Clinics and Research in Hepatology and Gastroenterology | 2018 | 6 Pages |
Abstract
HAI of 5-FU or mitomycin C is an alternative option in patients with predominant CRC LM, when they experience disease progression or do not tolerate HAI of oxaliplatin.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Simon Pernot, Guillaume Velut, Rapahel Hampig Kourie, Gregory Amouyal, Marc Sapoval, Anne Laure Pointet, Bruno Landi, Yosra Zaimi, Céline Lepère, Olivier Pellerin, Julien Taieb,